Patient Descriptions

The user has been using topical Minoxidil since April 2025 and Finasteride since September 2025, but their bald spot has worsened. They are considering switching to oral Minoxidil and have been advised to be patient, see a dermatologist, and possibly try additional treatments like derma rolling.

PP405 updates are seen as vague and lacking substance, causing frustration among users. Some users report positive effects from using minoxidil and dutasteride, while others remain skeptical about new treatments.

A doctor advised against taking finasteride after a hair transplant, suggesting the patient had reached their final balding pattern, but many users disagreed, recommending medications like minoxidil and finasteride to prevent further hair loss. The consensus was to seek a second opinion, as the advice seemed financially motivated rather than medically sound.

There is an inconsistency between the molecular weight and formula listed on EveryChem's product page and the analytical PDFs for 3HP and PP30, suggesting a possible error in the product description. Concerns are raised about EveryChem's business practices and lack of transparency in testing and manufacturing.

The user tried pyrilutamide for hair loss and noticed reduced scalp itch and improved skin but stopped due to mild heart sensations. They plan to update after consistent use, noting improved sleep when applied at night.

PP405 is a topical gel being tested for hair regrowth in adults with androgenetic alopecia. Volunteers aged 18-55 are needed for a 16-week trial in several US locations.